Print | PDF | Email Page

Life Sciences False Claims Act & Qui Tam Defense

Our lawyers' knowledge of statutory, regulatory and agency requirements, combined with deep experience in conducting internal investigations, allows us to provide our clients with a cost effective risk assessment early in a False Claims Act proceeding. These cases are among the most significant risks faced by life sciences companies today. More aggressive and better funded regulators, a sophisticated qui tam bar, more internal whistleblowers, and expanded statutory liability have resulted in staggering judgments and settlements against pharmaceutical and device manufacturers.

We work proactively during the investigation to dissuade government intervention or find a satisfactory resolution prior to full scale litigation. If the case proceeds to litigation, we target the complaint for dismissal, as many do not satisfy stringent FCA pleading requirements. Jones Day’s vast experience in litigating these cases, from large scale document production and depositions, to motion practice, through trial and appeal, allows us to advocate aggressively yet efficiently for our life sciences clients.
Featured Experience
Tina M. Tabacchi
Stephen G. Sozio